1. Home
  2. SCLX vs LNSR Comparison

SCLX vs LNSR Comparison

Compare SCLX & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$19.15

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Logo LENSAR Inc.

LNSR

LENSAR Inc.

HOLD

Current Price

$11.20

Market Cap

142.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
LNSR
Founded
2011
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Electronics
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
142.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLX
LNSR
Price
$19.15
$11.20
Analyst Decision
Hold
Hold
Analyst Count
1
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
122.8K
70.7K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,360,000.00
$59,141,000.00
Revenue This Year
N/A
$19.55
Revenue Next Year
$749.70
$35.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.02
52 Week Low
$3.60
$7.13
52 Week High
$34.27
$17.31

Technical Indicators

Market Signals
Indicator
SCLX
LNSR
Relative Strength Index (RSI) 51.13 56.52
Support Level $18.34 $10.14
Resistance Level $20.62 $10.48
Average True Range (ATR) 2.22 0.46
MACD -0.02 0.20
Stochastic Oscillator 32.91 82.46

Price Performance

Historical Comparison
SCLX
LNSR

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About LNSR LENSAR Inc.

LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.

Share on Social Networks: